SecurityDGLY / Digital Ally, Inc. (25382P208)
Chairman, CEO & PresidentRoss Stanton E
IndustryRadio and Television Broadcasting and Communications Equipment
Institutional Owners19
Institutional Shares370,795 - 4.82%
Common Shares Outstanding7,698,357 shares (as of 2018-06-30)
Institutional Value$ 1,262,000 USD

Institutional Stock Ownership and Shareholders

DGLY / Digital Ally, Inc. Institutional Ownership

Digital Ally, Inc. (NASDAQ:DGLY) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 370,795 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Honkamp Krueger Financial Services Inc /adv, Geode Capital Management, Llc, Citadel Advisors Llc, Virtu Financial LLC, Northern Trust Corp, Garner Asset Management Corp, and Ladenburg Thalmann Financial Services Inc.
Digital Ally, Inc. (NASDAQ:DGLY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR ROYAL BANK OF CANADA 2 2,002 100,000.00 0 5
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 550 600 9.09 1 1 0.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3,964 3,964 0.00 10 10 0.00
2018-08-14 13F-HR VANGUARD GROUP INC 162,538 162,538 0.00 422 382 -9.48
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 49,500 49,500 0.00 294 208 -29.25
2018-08-14 13F-HR Resources Investment Advisors, Inc. 362 362 0.00 1 1 0.00
2018-09-18 13F-HR/A NORTHERN TRUST CORP 12,379 29
2018-08-14 13F-HR VALLEY NATIONAL ADVISERS INC 42 42 0.00 0 0
2018-07-30 13F-HR/A Virtu Financial LLC 13,522 32
2018-07-19 13F-HR Garner Asset Management Corp 10,000 24
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 0 14,630 0 34
2017-02-10 13F-HR BlackRock Fund Advisors 889 889 0.00 5 4 -20.00
2018-08-09 13F-HR BlackRock Inc. 50,389 50,389 0.00 131 118 -9.92
2018-08-14 13F-HR MORGAN STANLEY 200 200 0.00 1 0 -100.00
2018-08-03 13F-HR Seacrest Wealth Management, Llc 4,550 100 -97.80 12 0 -100.00
2018-07-20 13F-HR Cornerstone Wealth Management, LLC 630 300
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 22,523 22,523 0.00 58 52 -10.34
2018-08-14 13F-HR UBS Group AG 1,000 1,589 58.90 3 3 0.00
2018-08-13 13F-HR HONKAMP KRUEGER FINANCIAL SERVICES INC /ADV 24,936 24,936 0.00 65 59 -9.23

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Digital Ally, Maker Of Police Body-Cameras, Is Back In Focus And Ready For Its Close-Up

2018-09-13 seekingalpha
Four years ago, after civil disturbances sparked by police shootings, Digital Ally, Inc.'s body-camera systems with innovative synchronization auto-activation technology were in high-demand, causing its stock to soar. (3-0)

Digital Ally, Inc (DGLY) CEO Stanton Ross on Q2 2018 Results - Earnings Call Transcript

2018-08-21 seekingalpha
This conference call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words believe, expect, anticipate, intend, estimate, may, should, could, will, plan, future, continue and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. (3-0)

Digital Ally Earnings: 10 Things to Know About Q2

2018-08-20 investorplace
Here are a few things to know about Digital Ally’s earnings report for the second quarter of the year. (3-0)

Hackers Can Edit Police Body Cam Footage Without Anybody Noticing - Motherboard

2018-08-14 motherboard.vice
Over the last decade or so, body cameras have been increasingly adopted by police agencies and touted as an effort to increase transparency in America's law enforcement agencies. In theory, body cameras can act as an “objective” third party during police encounters with civilians, thereby protecting civilians from excessive use of force and protecting police departments from unfounded claims of abuse. (3-0)

Axon: Long-Term Potential Remains Strong Despite 175% Surge

2018-05-23 seekingalpha
Axon, also known as Taser has skyrocketed by about 175% since I recommended the stock in a previous article. (3-1)

CUSIP: 25382P208